Background: Percutaneous coronary intervention with stent implantation is widely used for treatment of coronary artery disease preventing death or myocardial infarction over oral medication. However, it does not reduce the risk of deaths or myocardial infarctions or need of other interventions. Drug-eluting stents (DES) have an antiproliferative drug inhibiting excessive neointima growth and have lower rates of clinically indicated repeat revascularisation compared to bare-metal stents (BMS). Objectives: To report the survival outcome in a small group of patients receiving the new-generation DES compared to BMS over a six-year period. Methods: Fifteen patients of mean age 57.9 ± 9.3 years (range 44 to 71 years) with history of dizziness, unstable angina and myocardial infarction were recruited. However, all had stable angina pectoris at stent implantation except for two patients with either NSTEMI or STEMI. All patients received medications post-implantation, DES (n=9) and BMS (n=6). Cardiac biomarkers CKMB and Troponin T were also determined. Results and Discussion: Lower rate of restenosis (>70% stenosis) was seen in DES (11.1%) than in BMS (50%). No restenosis was seen in 33.3% of DES compared to 100% in BMS at six years of study. Mortality at twelve months was 11.1% (DES) and 16.7% (BMS) and by 64 months it was 33.3% (DES) and 50% (BMS). The survival outcome at six years was 66.7% (DES) and 50% (BMS). Conclusion: This small study favours the benefits derived from DES in having less restenosis occurrences in long-term implantation and lower mortality rates than seen in patients with BMS.